- Design
- Multicentre, double-blind, double-dummy randomised feasibility trial
- Population
- 21 adults with gout flare and chronic kidney disease (eGFR <60; mean age 72)
- Primary outcome
- Feasibility criteria; secondary time to pain reduction
- Effect
- Mean 7-day pain reduction about 47/100 in both arms; anakinra appeared faster (unconfirmed)
Gout flares in chronic kidney disease are hard to treat: NSAIDs are hazardous, colchicine needs dose adjustment and accumulates, and steroids worsen glycaemia and blood pressure. The ASGARD feasibility trial compared subcutaneous anakinra with intramuscular methylprednisolone for gout flares in people with an eGFR below 60.
This was a feasibility study and under-recruited — 21 randomised against a target of 32 — so it cannot establish efficacy. Within those limits, pain fell substantially over seven days in both arms, and anakinra appeared to reduce pain faster, a signal that needs a properly powered trial to confirm.
The usable message is that interleukin-1 blockade with anakinra is a mechanistically sound and reasonable option for a gout flare in a patient with kidney disease where the usual drugs are constrained — not a new standard, but a route worth knowing when the alternatives are poor. A definitive trial, with better community case-finding and faster treatment, is the next step.
- In chronic kidney disease, NSAIDs, colchicine and steroids for gout flares are each limited by renal or metabolic harm.
- ASGARD was a feasibility trial (21 randomised, under-recruited) and not powered to prove efficacy.
- Pain fell by about 47 of 100 points over 7 days; anakinra appeared to act faster, pending confirmation.
- Consider anakinra for a gout flare in kidney disease when the usual agents are contraindicated.
Why it matters
It keeps alive a genuinely useful option for a common problem where every first-line gout drug is compromised by kidney disease.
Don't overread it
A feasibility trial of 21 patients — it shows a definitive trial is doable and hints at faster relief, not that anakinra is superior.
The statistics, in plain English
Because the trial was a small, under-recruited feasibility study, the faster pain relief with anakinra is a hint, not proof — the numbers are too few and the comparison not powered to show a real difference.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free